How cell death shapes cancer

Cell Death and Disease

Volumn 6, Issue 3, 2015, Pages

  Labi, V ^a   Erlacher, M ^b,c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

APOPTOSIS; BONE MARROW DEPRESSION; CANCER SURVIVAL; CARCINOGENESIS; CELL EXPANSION; CELL LOSS; CELL PROLIFERATION; CELL STRESS; CLONE; DNA DAMAGE; GENETIC MODEL; GENOMIC INSTABILITY; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOUSE MODEL; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; ANIMAL; CELL DEATH; CELL TRANSFORMATION; GENETICS; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CELL DEATH; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; HUMANS; MICE; NEOPLASMS;

EID: 84988811185     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.20     Document Type: Review

References (145)

1. Harris CC. Chemical and physical carcinogenesis: Advances and perspectives for the 1990s. Cancer Res 1991; 51: 5023s-5044s.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Green DR, Evan GI. A matter of life and death. Cancer Cell 2002; 1: 19-30.
4. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495.
5. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41: 899-906.
6. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 1985; 82: 7439-7443.
7. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-1443.
8. Amundson SA, Myers TG, Fornace AJ Jr. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress. Oncogene 1998; 17: 3287-3299.
9. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
10. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: The critical roles of p53. Oncogene 2013; 32: 5129-5143.
11. Michalak E, Villunger A, Erlacher M, Strasser A. Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun 2005; 331: 786-798.
12. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ et al. p53-And drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
13. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation-And glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005; 106: 4131-4138.
14. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
15. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4: 321-328.
16. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337: 529-534.
17. Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT. Disrupted p53 function as predictor of treatment failure and poor prognosis in B-And T-cell non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5: 1085-1091.
18. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000; 10: 94-99.
19. Khanna KK, Jackson SP. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 2001; 27: 247-254.
20. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
21. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.
22. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785-6793.
23. Wu DW, Huang CC, Chang SW, Chen TH, Lee H. Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. Cell Death Differ e-pub ahead of print 17 October 2014.
24. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004-3016.
25. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. Concurrent upregulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413.
26. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005; 19: 427-434.
27. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM. Expression and transcriptional regulation of functionally distinct Bmf isoforms in B-chronic lymphocytic leukemia cells. Leukemia 2004; 18: 41-47.
28. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112-121.
29. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with In vitro and In vivo chemoresponses. Blood 1998; 91: 3379-3389.
30. Hamilton E, Pearce L, Morgan L, Robinson S, Ware V, Brennan P et al. Mimicking the tumour microenvironment: Three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Br J Haematol 2012; 158: 589-599.
31. Asslaber D, Grossinger EM, Girbl T, Hofbauer SW, Egle A, Weiss L et al. Mimicking the microenvironment in chronic lymphocytic leukaemia -where does the journey go? Br J Haematol 2013; 160: 711-714.
32. Llambi F, Green DR. Apoptosis and oncogenesis: Give and take in the BCL-2 family. Curr Opin Genet Dev 2011; 21: 12-20.
33. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs. Blood 1998; 92: 259-266.
34. Ploner C, Rainer J, Niederegger H, Eduardoff M, Villunger A, Geley S et al. The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia. Leukemia 2008; 22: 370-377.
35. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907-14912.
36. Calandra G, Bridger G, Fricker S. CXCR4 in clinical hematology. Curr Top Microbiol Immunol 2010; 341: 173-191.
37. Labi V, Grespi F, Baumgartner F, Villunger A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy? Cell Death Differ 2008; 15: 977-987.
38. Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009; 9: 321-326.
39. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
40. Mazumder S, Choudhary GS, Al Harbi S, Almasan A. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res 2012; 72: 3069-3079.
41. Rhiner C, Moreno E. Super competition as a possible mechanism to pioneer precancerous fields. Carcinogenesis 2009; 30: 723-728.
42. Okada H, Mak TW. Pathways of apoptotic and non-Apoptotic death in tumour cells. Nat Rev Cancer 2004; 4: 592-603.
43. Dahan P, Martinez GJ, Delmas C, Monferran S, Malric L, Zentkowski D et al. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: Possible involvement in radioresistance. Cell Death Dis 2014; 5: E1543.
44. Cotter TG. Apoptosis and cancer: The genesis of a research field. Nat Rev Cancer 2009; 9: 501-507.
45. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-333.
46. Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P et al. t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol 2014; 32: 1347-1355.
47. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
48. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992; 359: 554-556.
49. Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009; 28: 1274-1279.
50. Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 2014; 28: 58-70.
51. Frenzel A, Labi V, Chmelewskij W, Ploner C, Geley S, Fiegl H et al. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. Blood 2010; 115: 995-1005.
52. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169.
53. Michalak EM, Jansen ES, Happo L, Cragg MS, Tai L, Smyth GK et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 2009; 16: 684-696.
54. Jager R, Herzer U, Schenkel J, Weiher H. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 1997; 15: 1787-1795.
55. Jager R. Targeting the death machinery in mammary epithelial cells: Implications for breast cancer from transgenic and tissue culture experiments. Crit Rev Oncol Hematol 2007; 63: 231-240.
56. Evan G, Littlewood T. A matter of life and cell death. Science 1998; 281: 1317-1322.
57. Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 1999; 93: 2671-2678.
58. Gurova KV, Kwek SS, Koman IE, Komarov AP, Kandel E, Nikiforov MA et al. Apoptosis inhibitor as a suppressor of tumor progression: Expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer Biol Ther 2002; 1: 39-44.
59. Luke JJ, Van De Wetering CI, Knudson CM. Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability. Cell Death Differ 2003; 10: 740-748.
60. Moreno E, Basler K. dMyc transforms cells into super-competitors. Cell 2004; 117: 117-129.
61. Li W, Baker NE. Engulfment is required for cell competition. Cell 2007; 129: 1215-1225.
62. Meyer SN, Amoyel M, Bergantinos C, de la CC, Schertel C, Basler K et al. An ancient defense system eliminates unfit cells from developing tissues during cell competition. Science 2014; 346: 1258236.
63. Morata G, Ballesteros-Arias L. Developmental Biology Death to the losers. Science 2014; 346: 1181-1182.
64. Martins VC, Busch K, Juraeva D, Blum C, Ludwig C, Rasche V et al. Cell competition is a tumour suppressor mechanism in the thymus. Nature 2014; 509: 465-470.
65. Moreno E. Cancer: Darwinian tumour suppression. Nature 2014; 509: 435-436.
66. Dewanji A, Luebeck EG, Moolgavkar SH. A generalized Luria-Delbruck model. Math Biosci 2005; 197: 140-152.
67. Komarova NL, Wodarz D. Drug resistance in cancer: Principles of emergence and prevention. Proc Natl Acad Sci U S A 2005; 102: 9714-9719.
68. Enderling H, Anderson AR, Chaplain MA, Beheshti A, Hlatky L, Hahnfeldt P. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. Cancer Res 2009; 69: 8814-8821.
69. Enderling H, Hahnfeldt P. Cancer stem cells in solid tumors: Is 'evading apoptosis' a hallmark of cancer? Prog Biophys Mol Biol 2011; 106: 391-399.
70. Wodarz D, Komarova N. Can loss of apoptosis protect against cancer? Trends Genet 2007; 23: 232-237.
71. Labi V, Erlacher M, Krumschnabel G, Manzl C, Tzankov A, Pinon J et al. Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. Genes Dev 2010; 24: 1602-1607.
72. Michalak EM, Vandenberg CJ, Delbridge AR, Wu L, Scott CL, Adams JM et al. Apoptosispromoted tumorigenesis: Gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death. Genes Dev 2010; 24: 1608-1613.
73. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiationinduced tumorigenesis. Nat Genet 1994; 8: 66-69.
74. Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 2008; 28: 5391-5402.
75. Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J. Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol 2010; 8: E1000324.
76. Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 2010; 6: 309-322.
77. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006; 443: 214-217.
78. Labi V, Villunger A. PUMA-mediated tumor suppression: A tale of two stories. Cell Cycle 2010; 9: 4269-4275.
79. El Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
80. Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ et al. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest 2011; 121: 1722-1732.
81. Baumgartner F, Villunger A. Apoptosis: A barrier against cancer no more? Hepatology 2011; 54: 1121-1124.
82. Weber A, Boger R, Vick B, Urbanik T, Haybaeck J, Zoller S et al. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 2010; 51: 1226-1236.
83. Vick B, Weber A, Urbanik T, Maass T, Teufel A, Krammer PH et al. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 2009; 49: 627-636.
84. Mollereau B, Perez-Garijo A, Bergmann A, Miura M, Gerlitz O, Ryoo HD et al. Compensatory proliferation and apoptosis-induced proliferation: A need for clarification. Cell Death Differ 2013; 20: 181.
85. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008; 453: 314-321.
86. Bergmann A, Steller H. Apoptosis, stem cells, and tissue regeneration. Sci Signal 2010: 3re8.
87. Fan Y, Bergmann A. Apoptosis-induced compensatory proliferation. The Cell is dead. Long live the Cell!. Trends Cell Biol 2008; 18: 467-473.
88. Hwang JS, Kobayashi C, Agata K, Ikeo K, Gojobori T. Detection of apoptosis during planarian regeneration by the expression of apoptosis-related genes and TUNEL assay. Gene 2004; 333: 15-25.
89. Chera S, Ghila L, Dobretz K, Wenger Y, Bauer C, Buzgariu W et al. Apoptotic cells provide an unexpected source of Wnt3 signaling to drive hydra head regeneration. Dev Cell 2009; 17: 279-289.
90. Perez-Garijo A, Martin FA, Morata G. Caspase inhibition during apoptosis causes abnormal signalling and developmental aberrations in Drosophila. Development 2004; 131: 5591-5598.
91. Ryoo HD, Gorenc T, Steller H. Apoptotic cells can induce compensatory cell proliferation through the JNK and the Wingless signaling pathways. Dev Cell 2004; 7: 491-501.
92. Huh JR, Guo M, Hay BA. Compensatory proliferation induced by cell death in the Drosophila wing disc requires activity of the apical cell death caspase Dronc in a nonapoptotic role. Curr Biol 2004; 14: 1262-1266.
93. Fan Y, Bergmann A. Distinct mechanisms of apoptosis-induced compensatory proliferation in proliferating and differentiating tissues in the Drosophila eye. Dev Cell 2008; 14: 399-410.
94. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011; 17: 860-866.
95. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
96. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515: 577-581.
97. Sigurdson AJ, Jones IM. Second cancers after radiotherapy: Any evidence for radiationinduced genomic instability? Oncogene 2003; 22: 7018-7027.
98. Landier W, Bhatia S. Cancer survivorship: A pediatric perspective. Oncologist 2008; 13: 1181-1192.
99. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
100. Wong JR, Morton LM, Tucker MA, Abramson DH, Seddon JM, Sampson JN et al. Risk of subsequent malignant neoplasms in long-Term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol 2014; 32: 3284-3290.
101. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10: 501-514.
102. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: The complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118-129.
103. Alter BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program 2007: 29-39.
104. Soulier J. Fanconi anemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 492-497.
105. Alter BP, Giri N, Savage SA, Peters JA, Loud JT, Leathwood L et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010; 150: 179-188.
106. Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M. Apoptosis and prognostic factors in myelodysplastic syndromes. Leuk Lymphoma 2002; 43: 257-260.
107. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-3938.
108. Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, Zhivotovsky B et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003; 101: 1080-1086.
109. Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, Regairaz M et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012; 11: 36-49.
110. Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000; 408: 433-439.
111. Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RA et al. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer 2004; 39: 217-223.
112. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature e-pub ahead of print 8 December 2014.
113. Boehrer S, Ades L, Tajeddine N, Hofmann WK, Kriener S, Bug G et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 2009; 28: 2205-2218.
114. Ceccaldi R, Briot D, Larghero J, Vasquez N, Dubois dC, Chamousset D. Spontaneous abrogation of the G(2)DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J Clin Invest 2011; 121: 184-194.
115. Waisfisz Q, Morgan NV, Savino M, de Winter JP, van Berkel CG, Hoatlin ME. Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat Genet 1999; 22: 379-383.
116. Slape CI, Saw J, Jowett JB, Aplan PD, Strasser A, Jane SM et al. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. Blood 2012; 120: 2475-2483.
117. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-1478.
118. Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004; 23: 2746-2756.
119. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med 2005; 11: 725-730.
120. Labi V, Erlacher M, Kiessling S, Villunger A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ 2006; 13: 1325-1338.
121. Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl-2. Int J Cancer 1999; 84: 545-552.
122. Kaklamanis L, Savage A, Whitehouse R, Doussis-Anagnostopoulou I, Biddolph S, Tsiotos P et al. Bcl-2 protein expression: Association with p53 and prognosis in colorectal cancer. Br J Cancer 1998; 77: 1864-1869.
123. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997; 74: 346-358.
124. Meterissian SH, Kontogiannea M, Al Sowaidi M, Linjawi A, Halwani F, Jamison B et al. Bcl-2 is a useful prognostic marker in Dukes' B colon cancer. Ann Surg Oncol 2001; 8: 533-537.
125. Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Totsch M et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: Correlation with tumour stage and patient survival. Br J Cancer 1995; 72: 981-985.
126. Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Scholefield JH et al. Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients. World J Surg Oncol 2005; 3: 47.
127. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC. Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998; 1296: 82.
128. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 1995; 6: 1005-1010.
129. Castiglione F, Sarotto I, Fontana V, Destefanis M, Venturino A, Ferro S et al. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. Anticancer Res 1999; 19: 4555-4563.
130. Daidone MG, Veneroni S, Benini E, Tomasic G, Coradini D, Mastore M et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer 1999; 84: 580-586.
131. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J et al. BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010; 103: 668-675.
132. Friedrich K, Dimmer V, Haroske G, Lossnitzer A, Kasper M, Theissig F et al. Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers. Pathol Res Pract 1995; 191: 1114-1121.
133. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-Term survival in breast cancer. Am J Pathol 1994; 145: 1191-1198.
134. Kobayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T et al. Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat 1997; 42: 173-181.
135. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M et al. The Bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
136. Vargas-Roig LM, Cuello-Carrion FD, Fernandez-Escobar N, Daguerre P, Leuzzi M, Ibarra J et al. Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Mol Oncol 2008; 2: 102-111.
137. Villar E, Redondo M, Rodrigo I, Garcia J, Avila E, Matilla A. Bcl-2 expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol 2001; 22: 137-145.
138. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K et al. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res 1998; 18: 1989-1998.
139. Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C et al. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010; 10: 186.
140. Renouf DJ, Wood-Baker R, Ionescu DN, Leung S, Masoudi H, Gilks CB et al. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol 2009; 4: 486-491.
141. Shibata Y, Hidaka S, Tagawa Y, Nagayasu T. Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer. Anticancer Res 2004; 24: 1925-1928.
142. Zhao XD, He YY, Gao J, Zhao C, Zhang LL, Tian JY et al. High expression of Bcl-2 protein predicts favorable outcome in non-small cell lung cancer: Evidence from a systematic review and meta-Analysis. Asian Pac J Cancer Prev 2014; 15: 8861-8869.
143. Pillai K, Pourgholami MH, Chua TC, Morris DL. Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma? Am J Cancer Res 2013; 3: 312-322.
144. McDonald FE, Ironside JW, Gregor A, Wyatt B, Stewart M, Rye R. The prognostic influence of bcl-2 in malignant glioma. Br J Cancer 2002; 86: 1899-1904.
145. Inada T, Kikuyama S, Ichikawa A, Igarashi S, Ogata Y. Bcl-2 expression as a prognostic factor of survival of gastric carcinoma. Anticancer Res 1998; 18: 2003-2010.